AIDS-Related Mycoses : Current Progress in the Field and Future Priorities by Armstrong-James, Darius et al.
1 
 
AIDS-Related Mycoses: Current progress in the field and future priorities  1 
 2 
Darius Armstrong-James1*, Tihana Bicanic2, Gordon D. Brown3,4, Jennifer C. Hoving3,  3 
Graeme Meintjes3, Kirsten Nielsen5, and the Working Group from the EMBO-AIDS Related 4 
Mycoses Workshop (Akilmali A, Alupo P, Andrianopoulos A, Armstrong-James D, Barr D, 5 
Bauman S, Bicanic T, Botha A, Boulware D, Bradley S, Brand S, Brown G, Burgers W, Chari 6 
R, Chiller T, Cohen O, Dambuza I, Day J, Denning D, Edwards J, Fisher M, Frazer J, 7 
Garelnabi M, Gomez B, Govender N, Hanise P, Harrison J, Harison T, Heath CH, Hope W, 8 
Hoving J, Huppler Hullseik K, Jarvis J, Jenkins M, Kamuyango A, Kannambath S, Katende 9 
A, Kauffman C, Klausner J, Kolls J, Kwizera R, Lalloo DG, Le T, Lerm B, Letang E, Levitz S, 10 
Limper A, Longley N, Loyse A, Madu L, Maphanga T, Marakalala M, Mashao-Mphaphuli B, 11 
May R, Mbwanji G, Meintjes G, Meya D, Mhlanga M, Molloy S, Mthembu N, Mukaremera L, 12 
Nacher M, Ndiitwani D, Netea M, Nielsen K, Ogundeji A, Okurut S, Oladele R, Omondi F, 13 
Irchard A, Osherov N, Otieno P, Perez Casas C, Perfect J, Rhein J, Romani L, Rukasha I, 14 
Samie A, Schutz C, Schwartz I, Scriven J, Sebolai O, Seleteng Kopse L, Shikwambane-15 
Ntlemo G, Smulian G, Sobel J, Sriruttan C, Stone N, Trollope K, Tugeme L, Valentine M, 16 
Vreulink J, Wake R, Wasserman S, Wilkinson R, Williams D, Williamson P, Wood K, 17 
Youngchim S) 18 
 19 
1 Fungal Pathogens Laboratory, National Heart and Lung Institute, Imperial College London, SW7 20 
2AY UK 21 
 22 
2 Institute of Infection and Immunity, St. George’s University of London, London SW17 0RS3 23 
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 24 
7925, Cape Town, South Africa 25 
 26 
4 MRC Centre for Medical Mycology, Aberdeen Fungal Group, University of Aberdeen, Institute of 27 
Medical Sciences, Foresterhill, Aberdeen, AB25 2ZD, UK  28 
 29 
5 Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, 30 
55455 31 
 32 
*Corresponding Author 33 
Email: d.armstrong@imperial.ac.uk 34 
Tel: +4477905003385 35 
 36 
 37 
Abstract 38 
Opportunistic fungal infections continue to take an unacceptably heavy toll on the most 39 
disadvantaged living with HIV-AIDS, and are a major driver for HIV-related deaths. At the second 40 
EMBO AIDS-Mycoses Workshop, clinicians and scientists from around the world reported current 41 
progress and key priorities for improving outcomes from HIV-related mycoses.  42 
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Global burden of HIV-related fungal disease 47 
Whilst many fungi cause low grade superficial infections, these microorganisms are a major cause 48 
of high-mortality invasive infections in immunocompromised individuals[1]. Advanced HIV infection 49 
continues to be a major driver for invasive fungal diseases, despite the global scale-up of 50 
antiretroviral therapies (ART)[1]. Defining the global burden of fungal diseases presents a major 51 
challenge, as they are often insidious in nature, and there are intrinsic challenges in their 52 
diagnosis, as well as a global lack of capacity for fungal diagnostics[1]. Best estimates suggest 53 
there are up to a million invasive fungal infections per annum related to HIV-AIDS (primarily 54 
cryptococcosis, pneumocystosis, histoplasmosis, and talaromycosis (formerly penicilliosis)), with a 55 
consequent mortality of up to 500,000 per annum [2]. This places HIV-related fungal disease at 56 
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nearly the same level of mortality as other major infectious diseases such as malaria and 57 
tuberculosis[3, 4]. Current case fatality rates for cryptoccocal meningitis vary between 30% and 58 
70% for patients diagnosed and treated in sub-Saharan Africa[5, 6]. Recent data from the Amazon 59 
region for HIV-associated histoplasmosis indicates a 50% overall mortality rate at 1 year[7]. 60 
Studies in Uganda indicate on overall mortality of around 20% for HIV-related Pneumocystis 61 
pneumonia[8], and a mortality rate of 28% for HIV-associated talaromycosis in Viet Nam[9]. In 62 
addition, oral candidiasis is very common and associated with a high degree of morbidity if 63 
untreated[1].   64 
 65 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has established an ambitious 66 
treatment target known as 90-90-90 to control the AIDS epidemic(ii). But even if these targets are 67 
reached, there will still be a substantial burden of fungal disease in patients who present for care 68 
late or disengage from or fail ART. Despite this, fungal disease has not had the same level of focus 69 
from the global community, although as a result of recent efforts from the medical mycology 70 
community, we hope this is now changing. 71 
 72 
At the inaugural meeting of the EMBO AIDS-Mycoses Working Group in Cape Town, South Africa 73 
in July 2013, 5 key goals were identified to improve outcomes from these deadly diseases: 74 
 75 
1. Better epidemiological surveillance for HIV-related fungal diseases. 76 
2. Better laboratory and point-of-care testing. 77 
3. Improved access to existing drugs. 78 
4. Expansion of capacity for medical mycology training. 79 
5. Increased funding for development of diagnosis, treatment and implementation programmes, 80 
especially in resource-poor settings.  81 
 82 
Recent progress in the field 83 
As part of ongoing efforts to stem the tide of fungal disease, over 100 researchers spearheading 84 
the battle against HIV-related fungal diseases in Africa, Asia, North and South America, Europe 85 
and Australasia met at the 2nd EMBO AIDS-Mycoses Workshop for three days in July 2016 in 86 
Cape Town, South Africa, to discuss current progress in the field and future priorities. 87 
 88 
The workshop was notable for the geographic breadth of participants, as well as excellent 89 
coverage for all the major HIV-related fungal diseases. The major topics discussed were 90 
epidemiology and public health, diagnostics, host-pathogen interactions, immunology, drug 91 
resistance, treatment strategies, new antifungal drugs, and vaccines. Detailed updates were given 92 
on epidemiology and public health aspects of the major AIDS-related mycoses including 93 
cryptococcosis, histoplasmosis, talaromycosis and pneumocystosis. In addition, newly recognized 94 
HIV-associated invasive fungal infections due to Emmonsia spp. (recently renamed Emergomyces) 95 
were highlighted. These infections appear to be unique to Southern Africa, and the clinical 96 
presentation mimics disseminated histoplasmosis. A notable observation was that whilst 97 
antiretroviral roll out appears to have had some impact on the incidence of cryptococcal meningitis 98 
in recent years, half of all cases occur after ART has been established[10]. When taken in the 99 
context of the global failure to reduce new HIV infections, emerging HIV drug resistance and 100 
challenges in retaining patients in ART care in resource-limited settings, it is clear that the ongoing 101 
epidemic of cryptococcal meningitis will be sustained. The high rates of HIV-associated infection 102 
and mortality from histoplasmosis in Latin America and talaromycosis in South and South East 103 
Asia were also highlighted[9, 11]. Key highlights in fundamental research in AIDS-related mycoses 104 
included genomics-based studies of cryptococcal evolution and resistance in the host, a number of 105 
studies detailing aspects of metabolic adaptation of Cryptococcus neoformans and Talaromyces 106 
marneffei in the host, and descriptions of the latest discoveries in understanding the innate and 107 
adaptive immune responses to Pneumocystis spp.  108 
 109 
A number of advances in the development and implementation of point-of-care-based testing 110 
(POCT) strategies were highlighted during the meeting. In particular, there has been enormous 111 
progress with the implementation of cryptococcal lateral flow device-based screening programmes 112 
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in sub-Saharan Africa. South Africa has recently implemented national reflex laboratory screening 113 
with a projected 250 000 persons estimated to screened per annum[12]. The strategy of treating 114 
antigen-positive patients reduces the likelihood of future cryptococcal meningitis[13]. Further 115 
progress was also reported with the development of rapid tests for Talaromyces marneffei and 116 
Histoplasma capsulatum infection.  117 
 118 
Access to currently available antifungal medicines as well as the development of novel antifungal 119 
drugs is an urgent priority, due to the limited drug classes and emerging resistance to triazoles. 120 
Planned recruitment to the AMBITION study was outlined (intermittent high dose AmBisome 121 
[liposomal amphotericin B] on a high dose fluconazole backbone for cryptococcal meningitis 122 
induction therapy in sub-Saharan Africa), as well as current Phase 1/2 studies for VT-1129, a new 123 
oral agent for cryptococcal disease, progress of the ACTA trial (oral fluconazole plus flucytosine or 124 
one week amphotericin B-based therapy versus two weeks amphotericin B-based therapy) and the 125 
ASTRO trial (Adjunctive Sertraline for the Treatment of HIV-associated cryptococcal meningitis). 126 
There continues to be inadequate access to flucytosine, amphotericin B and itraconazole in 127 
countries with major burdens of either cryptococcal meningitis or endemic mycoses. The 128 
emergence of triazole resistance in both Cryptococcus neoformans and Aspergillus fumigatus was 129 
also discussed[14, 15]. Notable progress has been made in understanding the genetic basis for the 130 
emergence of cryptococcal heteroresistance during therapy, and combination antifungal strategies 131 
to limit this. 132 
 133 
Advocacy for fungal diseases continues to gather pace, through the Global Action Fund for Fungal 134 
Infections(GAFFI) (i), the Cryptococcal Meningitis Advocacy Group(CryptoMAG) (iii), and the 135 
planned establishment of new groups focused on pneumocystosis and histoplasmosis. Whilst 136 
CryptoMAG successfully proposed the addition of flucytosine and amphotericin B to the essential 137 
medicines list, recent attempts to include itraconazole, a crucial drug for histoplasmosis, 138 
talaromycosis, and aspergillosis, on the WHO(World Health Organisation)’s essential medicines list 139 
have been unsuccessful. Furthermore, none of these AIDS-related mycoses are currently 140 
classified as neglected tropical diseases by the WHO.  141 
 142 
Key priorities for the future 143 
During the meeting, there was a major focus on discussing the key priorities to move the field 144 
forward, and 5 priorities were identified: 145 
 146 
1. Better collaborative working structures for basic scientists and clinical researchers to 147 
accelerate translational medicine. The meeting itself acted as an environment in which basic 148 
scientists and clinical researchers intensively interacted. Promoting greater interaction in the 149 
future will lead to accelerated translation. The 3rd AIDS-related Mycoses Conference is planned 150 
in 3 years’ time.  151 
 152 
2. Better diagnostics and improved surveillance. It is particularly apparent that without POCTs 153 
for the major AIDS-related mycoses these infections remain difficult to diagnose, and treat, and 154 
their true global burden remains very difficult to ascertain.   155 
 156 
3. Access to established medicines, as well as development of new medicines and 157 
vaccines. Access in particular to flucytosine, amphotericin B, and itraconazole are particularly 158 
patchy, and liposomal amphotericin B (Ambisome) remains very expensive in many countries. 159 
Acceleration of vaccination programmes should be a key priority, but will be challenging due to 160 
the difficulties in eliciting immune responses in immunocompromised people.  161 
 162 
4. Consolidation and extension of consortia for the delivery of multi-centre clinical trials. 163 
Whilst there are major groups working in the area of cryptococcal meningitis, better cohesion 164 
and extension to other AIDS-related mycoses will enable more rapid progress in this area. 165 
  166 
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5. Extension of current advocacy groups and public engagement. New advocacy groups are 167 
being established, based on CryptoMAG, covering histoplasmosis and pneumocystis. GAFFI is 168 
currently supporting the Kenyan government in an ambitious 5-year development program(ii).  169 
 170 
Concluding remarks 171 
Invasive fungal infections continue to be a major cause of mortality in the context of advanced HIV 172 
infection globally. The medical mycology community made significant recent progress in delivering 173 
novel diagnostic and therapeutic strategies to limit mortality from these infections, and there are 174 
some encouraging novel therapies on the horizon. However, engagement of major funding bodies 175 
and governmental and non-governmental organizations is urgently needed to enable substantial 176 
reductions in the unacceptably high morbidity and mortality from the AIDS-related mycoses.  177 
 178 
Resources 179 
i. http://www.unaids.org/en/resources/documents/2014/90-90-90 180 
ii. http://www.gaffi.org 181 
iii. http://preventcrypto.org/about-us/ 182 
  183 
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